SAVA · Cassava Sciences Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $4.54M | - | $3.96M | $5.12M | $13.67M | - | $17.68M | $24.97M | $16.23M | - |
| SG&A | $6.62M | - | $7.91M | $40.28M | $10.92M | - | $12.95M | $46.20M | $3.70M | - |
| Total Operating Expenses | $11.17M | - | $11.86M | $45.39M | $24.59M | - | $30.62M | $61.40M | $19.93M | - |
| D&A | $243.0K | - | $200.0K | $200.0K | $220.0K | - | $228.0K | $244.0K | $250.0K | - |
| Operating Income | ($11.17M) | - | ($11.86M) | ($45.39M) | ($24.59M) | - | ($30.62M) | ($61.40M) | ($19.93M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($10.33M) | - | ($10.81M) | ($44.22M) | ($23.40M) | - | ($27.94M) | $6.16M | $25.04M | - |
| EPS - Basic | ($0.21) | - | ($0.22) | ($0.92) | ($0.48) | - | ($0.58) | $0.13 | $0.58 | - |
| EPS - Diluted | - | - | ($0.22) | ($0.92) | ($0.48) | - | ($0.58) | $0.13 | ($0.43) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $86.57M | $95.50M | $106.08M | $112.38M | $117.33M | $128.57M | $148.98M | $207.29M | $124.17M | $121.14M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $87.96M | $97.71M | $108.91M | $114.82M | $120.15M | $136.53M | $202.55M | $222.12M | $134.00M | $129.63M |
| Total Assets | $108.37M | $118.36M | $129.73M | $135.38M | $140.93M | $157.53M | $223.75M | $243.57M | $155.72M | $151.66M |
| Current Liabilities | $40.12M | $43.83M | $48.05M | $47.33M | $13.24M | $11.75M | $57.03M | $54.59M | $77.12M | $14.20M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $40.23M | $43.95M | $48.16M | $47.41M | $13.32M | $11.83M | $57.11M | - | - | $14.20M |
| Stockholders' Equity | $68.14M | $74.40M | $81.57M | $87.97M | $127.62M | $145.70M | $166.64M | $188.97M | $78.60M | $137.47M |
| Retained Earnings | ($506.42M) | ($496.08M) | ($483.55M) | ($472.74M) | ($428.51M) | ($405.11M) | ($377.51M) | ($349.57M) | ($355.73M) | ($380.77M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.88M) | - | - | - | ($11.34M) | - | - | - | ($19.13M) | - |
| Investing Cash Flow | - | - | - | - | $0 | - | - | - | $0 | - |
| Financing Cash Flow | ($51.0K) | - | - | - | $90.0K | - | - | - | $22.16M | - |
| CapEx | - | - | - | - | $0 | - | - | - | $0 | - |
| Free Cash Flow | - | - | - | - | ($11.34M) | - | - | - | ($19.13M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | 0.48 | - | - | - | -0.76 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | 0.0% | 0.0% | - |
| Return on assets | -9.5% | - | -8.3% | -32.7% | -16.6% | - | -12.5% | 2.5% | 16.1% | - |
| Return on equity | -15.2% | - | -13.2% | -50.3% | -18.3% | - | -16.8% | 3.3% | 31.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.19 | 2.23 | 2.27 | 2.43 | 9.08 | 11.62 | 3.55 | 4.07 | 1.74 | 9.13 |
| Quick ratio | 2.19 | 2.23 | 2.27 | 2.43 | 9.08 | 11.62 | 3.55 | 4.07 | 1.74 | 9.13 |
| Cash ratio | 2.16 | 2.18 | 2.21 | 2.37 | 8.86 | 10.94 | 2.61 | 3.80 | 1.61 | 8.53 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.59 | 1.59 | 1.59 | 1.54 | 1.10 | 1.08 | 1.34 | 1.29 | 1.98 | 1.10 |
| Liabilities / Assets | 0.37 | 0.37 | 0.37 | 0.35 | 0.09 | 0.08 | 0.26 | - | - | 0.09 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 54.6% | - | 61.3% | 26.1% | -23.3% | - | -9.8% | -113.4% | 24.8% | - |
| Net income growth (YoY) | 55.9% | - | 61.3% | - | - | - | -8.9% | - | - | - |
| EPS growth (YoY) | - | - | 62.1% | - | -11.6% | - | - | - | 2.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 40.7% | - | - | - | -40.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -46.6% | -48.9% | -51.1% | -53.4% | 62.4% | 6.0% | 7.4% | 5.4% | -61.5% | -39.6% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CASSAVA SCIENCES INC against the 5 most active filers in the same SIC group.